Test Price
1,200 AED✅ Home Collection Available
PD-L1 (SP263) Immunohistochemistry Test in UAE | 1200 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for FFPE blocks and biopsy slides.
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance on result interpretation by DHA-licensed specialist.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731 – instant confirmation before visit.
Test Overview & Methodology
The PD-L1 (SP263) immunohistochemistry test quantifies Programmed Death-Ligand 1 expression on tumor cells using the Ventana SP263 antibody clone, standardized on automated staining platforms. In the UAE, it is a DHA-recognized companion diagnostic essential for immunotherapy candidacy in non‑small cell lung cancer, urothelial carcinoma, and other malignancies.
| Feature | Our Test (PD-L1 SP263) | Closest Alternative |
|---|---|---|
| Methodology | Quantitative IHC, Ventana Benchmark Ultra, digital scoring | Other PD-L1 clones (22C3, 28‑8) – manual read |
| Turnaround | 5 working days (block), 7 days large complex | 7–10 days |
| Clinical Concordance | 99.9% Diagnostic Sensitivity | Variable, lab‑dependent |
| Specimen | FFPE block or formalin‑fixed tissue (room temp shipment) | Often requires fresh frozen |
Physician Insight & Safety Protocols
“PD-L1 SP263 IHC on FFPE tissue provides critical quantitative data for immunotherapy decisions. From a diagnostic radiology perspective, the biopsy site selected under imaging guidance directly influences tissue representativeness and scoring reliability. The Tumor Proportion Score must always be evaluated alongside full histopathology, staging, and clinical context — no single biomarker dictates the entire treatment pathway. Patients should understand that this result opens a discussion, not a verdict.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Important Clinical Advisory
Do not discontinue, alter, or initiate any prescribed medication — including immunotherapy, targeted therapy, or supportive agents — based solely on this test result. Treatment decisions require comprehensive evaluation by your treating oncologist incorporating the complete histopathology report, imaging findings, and clinical status.
Patient Safety & Exclusion Criteria
- Specimen Rejection: Insufficient tumor content (<100 viable tumor cells), improper fixation (non‑10% neutral buffered formalin), or decalcified samples.
- Clinical Contraindications: Test not indicated for hematologic malignancies or cytology specimens without cell block.
- Emergency Red Flags: If you experience acute respiratory distress, severe uncontrolled pain, or signs of tumor lysis syndrome, seek immediate emergency care — do not wait for test results.
- Pediatric Advisory: For minors, guardian consent and a pediatric oncology consultation are mandatory prior to specimen collection, in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. How does PD-L1 SP263 testing determine my eligibility for immunotherapy?
The PD‑L1 SP263 assay quantitatively measures PD-L1 expression on tumor cell membranes using the Tumor Proportion Score (TPS). Results are interpreted alongside your complete pathology report, biopsy site, and clinical history to guide immunotherapy candidacy. A positive result indicates potential benefit from checkpoint inhibitor therapy, while a negative result helps avoid unnecessary treatment.
2. What type of tissue sample is required and how should it be prepared?
A formalin-fixed paraffin-embedded (FFPE) tissue block or tumor biopsy placed in 10% neutral-buffered formalin is required. Samples must be accompanied by the original histopathology report, biopsy site details, and relevant clinical history to ensure proper evaluation. Decalcified specimens or those with insufficient tumor content will be rejected.
3. How is the FFPE tissue block or biopsy transported to your laboratory?
Our Secure Medical Courier Solid Tissue Specimen Retrieval service coordinates ISO-certified, temperature-controlled transport of your archival tissue sample. Simply contact us via WhatsApp at +971 54 548 8731 to schedule a pickup. The courier will collect the FFPE block or biopsy slides directly from your location using compliant packaging and chain-of-custody documentation.
4. When will I receive my test results and how are they delivered?
Results are available within 5 working days for standard FFPE blocks and up to 7 days for complex or large specimens. Your referring physician receives the detailed pathology report electronically, and you will receive a complimentary telephonic consultation with a DHA-licensed specialist to explain the findings and next steps.
UAE Regulatory & Data Privacy Adherence
This test is performed at DNA Labs UAE under DHA Facility License No. 1143. All patient data, including clinical history, test results, and personal identifiers, are processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent, data confidentiality, and secure handling of medical records are foundational to our laboratory operations. Your information is used solely for diagnostic purposes and will not be shared without your explicit authorization.
Clinical & Logistical Metadata
| Test Name | PD-L1 (SP263) Immunohistochemistry Test |
| Price (AED) | 1200 |
| Turnaround Time | 5 working days (standard block), 7 days (complex cases) |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block or Tumor Biopsy in 10% neutral buffered formalin |
| Methodology Used | Quantitative Immunohistochemistry (IHC) – Ventana SP263 Clone on Benchmark Ultra Platform with Digital H-Score / TPS Scoring |
| ICD-10-CM Code | C34.9 (Malignant neoplasm of unspecified part of bronchus or lung), Z51.12 (Encounter for antineoplastic immunotherapy) |
| LOINC Code | 102645-9 (PD-L1+ tumor cells/Total tumor cells in Tissue by Immune stain) |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians